Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Transcutaneous spinal cord stimulation with 4-aminopyridine and intensive rehab for chronic spinal cord injury

Official title: Combination Therapy: Transcutaneous Spinal Stimulation (TSS), 4 Aminopyridine (4 AP), and Intensive Rehabilitation for Motor Recovery After Spinal Cord Injury

Run by TryAbility LLC · NCT07922122 · Data updated 2026-11-12

This pilot study tests whether combining noninvasive spinal stimulation, dalfampridine, and rigorous rehab is safe and feasible for adults with chronic spinal cord injury and whether it can help improve movement and walking.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment8 (estimated)
SponsorTryAbility LLC
Academic / other
Locations1 site (Downers Grove, Illinois)
StatusRecruiting
StartedJune 6, 2026
Main results expectedJuly 8, 2027
Study endsSeptember 8, 2027
Registry record updatedNovember 6, 2026
Trial IDNCT07922122 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–75 with chronic SCI (≥12 months post-injury), medically stable, currently prescribed dalfampridine, and able to participate in intensive rehabilitation.

Probably not a fit

Patients not experiencing functional improvements or who have contraindications to dalfampridine or electrical stimulation may see no meaningful benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-arm pilot study will enroll eight adults with chronic spinal cord injury (at least 12 months post-injury) to receive a 12-week outpatient program combining transcutaneous spinal cord stimulation, dalfampridine, and intensive physical and occupational therapy. The objective is to assess safety and feasibility of the combined approach in a real-world rehabilitation setting and to explore preliminary changes in upper and lower extremity motor function, strength, ambulation, balance, and functional mobility. Participants will undergo about three treatment sessions per week, each session including 60 minutes of physical therapy and 60 minutes of occupational therapy, alongside ongoing dalfampridine as prescribed by their treating physician. The study builds on the rationale that neuromodulation and pharmacologic augmentation may enhance activity-dependent neuroplasticity when paired with task-specific rehabilitation. Outcomes from this pilot will inform whether this multimodal strategy merits further investigation in larger, controlled trials.

Why it matters

Potential benefit: If successful, participants may experience improvements in motor function and mobility, potentially translating to better independence in daily activities.

How similar studies have gone: Previous work suggests neuromodulation and pharmacologic strategies can support motor activation after SCI, but this specific combination is novel and at the feasibility stage.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Adults between 18 and 75 years of age.

Diagnosis of chronic spinal cord injury (SCI), at least 12 months post-injury.

Medically stable and able to participate in intensive rehabilitation therapy.

Able to provide informed consent.

Currently receiving 4-aminopyridine (dalfampridine) prescribed by their treating physician as part of routine medical care. Criteria:

\-

Exclusion Criteria:

* History of uncontrolled seizure disorder.

Contraindication to 4-aminopyridine (dalfampridine).

Uncontrolled cardiovascular disease.

Presence of implanted electrical medical devices, including pacemakers or neurostimulators.

Pregnancy.

Severe pressure injuries that prevent safe electrode placement.

Known or suspected significant cognitive impairment, dementia, intellectual disability, or other neurological or psychiatric conditions that interfere with comprehension of study requirements or the ability to complete study assessments.

Where it's running

  • TryAbility Neuro Recovery Center
    Downers Grove, Illinois, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.